for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cardlytics Inc

CDLX.OQ

Latest Trade

66.89USD

Change

0.00(0.00%)

Volume

285,523

Today's Range

64.46

 - 

73.01

52 Week Range

22.26

 - 

107.50

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Cardlytics Reports Q4 Earnings Per Share Of $0.12

March 3 (Reuters) - Cardlytics Inc <CDLX.O>::CARDLYTICS ANNOUNCES FOURTH QUARTER AND FISCAL YEAR 2019 FINANCIAL RESULTS.Q4 EARNINGS PER SHARE $0.12.Q4 REVENUE $69.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF $63.9 MILLION.Q4 NON-GAAP EARNINGS PER SHARE $0.18.Q4 EARNINGS PER SHARE ESTIMATE $0.04 -- REFINITIV IBES DATA.SEES Q1 2020 REVENUE $43.5 MILLION - $46.5 MILLION.SEES Q1 2020 BILLINGS $64.0 MILLION - $69.0 MILLION.Q1 REVENUE VIEW $52.8 MILLION -- REFINITIV IBES DATA.QTRLY BILLINGS, A NON-GAAP METRIC, WAS $100.9 MILLION, AN INCREASE OF 43.7% YEAR-OVER-YEAR.

Cardlytics Sees Q4 Revenue Between $68.5 Mln And $69.5 Mln

Jan 13 (Reuters) - Cardlytics Inc <CDLX.O>::CARDLYTICS ANNOUNCES PRELIMINARY FOURTH QUARTER 2019 FINANCIAL RESULTS.SEES Q4 2019 REVENUE $68.5 MILLION TO $69.5 MILLION.SEES Q4 TOTAL BILLINGS IS EXPECTED TO BE BETWEEN $99.0 MILLION AND $101.0 MILLION..Q4 REVENUE VIEW $59.0 MILLION -- REFINITIV IBES DATA.EXPECT OUR FI MAU GROWTH TO CONTINUE IN 2020.

Cardlytics Announces Third Quarter 2019 Financial Results

Nov 12 (Reuters) - Cardlytics Inc <CDLX.O>::CARDLYTICS ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.33.Q3 REVENUE $56.4 MILLION VERSUS REFINITIV IBES ESTIMATE OF $50.1 MILLION.Q3 NON-GAAP EARNINGS PER SHARE $0.03.Q3 EARNINGS PER SHARE ESTIMATE $-0.15 -- REFINITIV IBES DATA.SEES 2019 REVENUE $196.0 MILLION - $200.0 MILLION.SEES 2019 BILLINGS $297.0 MILLION - $303.0 MILLION.

Cardlytics Inc - Announced Pricing Of An Underwritten Public Offering Of 2.69 Million Shares Priced At $34 Per Share

Cardlytics Inc <CDLX.O>::CARDLYTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.CARDLYTICS INC - ANNOUNCED PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 2.69 MILLION SHARES PRICED AT $34 PER SHARE.

Cardlytics Announces Proposed Public Offering Of Common Stock

Sept 9 (Reuters) - Cardlytics Inc <CDLX.O>::CARDLYTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.SAYS OFFERING 2.69 MILLION COMMON SHARES.OF 2.69 MILLION SHARES, 1.5 MILLION ARE BEING OFFERED BY CO & 1.19 MILLION SHARES BY EXISTING STOCKHOLDERS.

Cardlytics Reports Q2 Loss Per Share Of $0.29

Aug 8 (Reuters) - Cardlytics Inc <CDLX.O>::CARDLYTICS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.29.Q2 REVENUE $48.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $43.8 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $-0.23 -- REFINITIV IBES DATA.Q2 NON-GAAP LOSS PER SHARE $0.12.QTRLY BILLINGS $73.8 MILLION, UP 43%.SEES FY 2019 REVENUE $180.0 MILLION - $190.0 MILLION.SEES Q3 BILLINGS $70.0 MILLION - $76.0 MILLION.SEES FY 2019 BILLINGS $275.0 MILLION - $290.0 MILLION.SEES Q3 REVENUE $46.0 MILLION - $50.0 MILLION.

Cardlytics Q2 Non-Gaap Loss Per Share $0.12

Aug 8 (Reuters) - Cardlytics Inc <CDLX.O>::CARDLYTICS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.29.Q2 REVENUE $48.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $43.8 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $-0.23 -- REFINITIV IBES DATA.Q2 NON-GAAP LOSS PER SHARE $0.12.QTRLY BILLINGS $73.8 MILLION, UP 43%.SEES FY 2019 BILLINGS $275.0 - $290.0.SEES FY 2019 REVENUE $180.0 - $190.0.SEES Q3 $46.0 MILLION - $50.0 MILLION.SEES Q3 BILLINGS $70.0 MILLION - $76.0 MILLION.

Cardlytics Inc Files For Mixed Shelf Of Upto $100 Mln

July 27 (Reuters) - Cardlytics Inc <CDLX.O>::CARDLYTICS INC FILES FOR MIXED SHELF OF UPTO $100 MILLION - SEC FILING.CARDLYTICS INC IN ADDITION, SECONDARY OFFERING OF UP TO 4.0 MILLION SHARES OF COMMON STOCK.

Cardlytics Says Co And Pacific Western Bank Entered Second Amendment Dated May 21, 2018 - SEC Filing

May 14 (Reuters) - Cardlytics Inc <CDLX.O>::CARDLYTICS SAYS CO AND PACIFIC WESTERN BANK ENTERED INTO A SECOND AMENDMENT DATED MAY 21, 2018 - SEC FILING.CARDLYTICS INC - PURSUANT TO AMENDMENT, CO & LENDER AGREED TO INCREASE ASSET-BASED REVOLVING LINE OF CREDIT UNDER LSA FROM $30.0 MILLION TO $40.0 MILLION.CARDLYTICS INC - COMPANY AGREED TO REPAY $10.0 MILLION OF PRINCIPAL BALANCE OF TERM LOAN OUTSTANDING UNDER LSA ON MAY 14, 2019.CARDLYTICS INC - AMENDMENT ALSO EXTENDED MATURITY DATE FOR BORROWINGS UNDER LSA TO MAY 14, 2021.

Cardlytics Reports Q4 GAAP Loss Per Share Of $0.53

March 5 (Reuters) - Cardlytics Inc <CDLX.O>::CARDLYTICS ANNOUNCES FOURTH QUARTER AND FISCAL YEAR 2018 FINANCIAL RESULTS.Q4 GAAP LOSS PER SHARE $0.53.Q4 REVENUE $47.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $45.8 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $-0.17 -- REFINITIV IBES DATA.Q4 NON-GAAP LOSS PER SHARE $0.06.SEES Q1 2019 REVENUE IN THE RANGE OF $34.5 MILLION TO $36.5 MILLION.SEES Q1 2019 NON-GAAP ADJUSTED CONTRIBUTION IN THE RANGE OF $15.5 MILLION TO $16.5 MILLION.Q4 REVENUE VIEW $45.8 MILLION -- REFINITIV IBES DATA.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up